Test your hereditary cancer risk with GeneMate®.

By understanding your hereditary cancer risk, you and your care provider can develop a plan to significantly reduce your risk or enable early detection through more frequent screening. GeneMate® provides a comprehensive risk assessment through the combination of genetic testing and an assessment of family cancer history.

Order
Genemate DNA-test - Vid ärftligt orsakad cancer kan din genprofil ha betydelse för dina behandlingsval

Lifetime cancer risk

66.6% Utvecklar inte cancer, 33.3% Utvecklar cancer och 10% ärftlig cancer

How common is cancer?

Roughly one third of the population will develop cancer in their lifetime, and 5-10% of all cancer is hereditary. Still, 97% of those at risk for hereditary cancer remain unidentified.

Hereditary cancer may be due to one underlying genetic variant – also called a mutation – or a combination of several variants and environmental factors.

Certain cancers are more strongly linked to hereditary factors than others. Colorectal cancer is the third most common cancer worldwide, and as much as one third of all cases are thought to be hereditary.

Know your risk with GeneMate®

Through GeneMate® you can identify whether you carry an increased risk for hereditary cancer. GeneMate® combines genetic testing with a review of your family’s cancer history for a comprehensive assessment.

Det genetiska testet visar om du har någon sjukdomsorsakande variant (mutation) i din arvsmassa (DNA).

An assessment of the DNA in your saliva reveals whether you carry a genetic variant (mutation) that increases your risk of cancer.

Bedömningen baseras på ett genetiskt test och en granskning av din familjehistoria av cancer

Your family’s cancer history is reviewed for clinical indicators of hereditary cancer.

Is GeneMate® right for me?

GeneMate® is intended for adults 18 years of age or older who would like to know if they have an increased risk for hereditary cancer. Please note that pathogenic variants are rare in the general population. The probability is increased, however, if any of the following are true:

  • If you or a close relative1 have been diagnosed with cancer at a young age, such as breast cancer before 40. What is considered young varies by cancer type.
  • If you or a close relative have had several cancer diagnoses.
  • If you or a close relative have had a rare cancer diagnosis.
  • If several close relatives have had the same or related cancer diagnoses. Colorectal cancer and uterine cancer, for example, are related cancer types.

Research shows, however, that many individuals with pathogenic variants do not meet these criteria.

Still wondering if GeneMate® is right for you? Get in touch at support@icellate.se and we’ll be happy to answer your questions.

1 Close relatives include: parents, siblings, half siblings, children, grandchildren, grandparents, aunts, uncles, nieces, and nephews.

How does GeneMate® work?

1

Order your GeneMate® test online.

4 995 kr

Order
2

A sample collection kit will be delivered directly to your mailbox for at-home saliva collection.

3

Activate your test online and return your sample in the same box it came in.

4

Access your report online within 4-6 weeks.

5

Our clinical team is always available for consultation.

6

Increased risk? We’ll refer you to the appropriate care provider.

Your hereditary risk lies in your DNA

While genetic variants are rare, they say a lot about an individual’s risk of developing certain cancers. A woman with a pathogenic variant in the gene BRCA1, for example, has a 50-80% risk of developing breast cancer, while the average woman has a risk of only 10%.

Breast Cancer Risk

Risk att utveckla bröstcancer

Ovarian Cancer Risk

Risk att utveckla äggstockscancer
Women with a BRCA1 mutation
Average woman

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.

Get to know your DNA with GeneMate®

Analytical validation of the GeneMate® test has shown >99% sensitivity, >99% specificity, and >99.9% reproducibility. In other words, GeneMate® identifies existing gene variants at an exceedingly high rate (sensitivity), while maintaining minimal risk for false positives (specificity).

The GeneMate® panel covers all cancer types that are known to have a clinically significant hereditary component.

Breast cancer
Colorectal cancer
Uterine cancer
Ovarian cancer
Urinary tract cancer
Melanoma
Pancreatic cancer
Stomach cancer
Prostate cancer
Paraganglioma & pheocromocytoma
Brain cancer
Retinoblastoma
Thyroid cancer

The GeneMate® test’s 41-gene panel has been thoughtfully developed with regard to clinical relevance and actionability. Genes have been selected in accordance with Swedish and American clinical care guidelines2.

APC ATM BAP1 BMPR1A BRCA1
BRCA2 BRIP1 CDH1 CDKN2A CHEK2
DICER1 EPCAM MAX MEN1 MLH1
MSH2 MSH6 MUTYH NF1 NF2
PALB2 PMS2 PTEN RAD51C RAD51D
RB1 RET SDHA SDHAF2 SDHB
SDHC SDHD SMAD4 SMARCB1 STK11
TMEM127 TP53 TSC1 TSC2 VHL
WT1

Those who meet certain clinical criteria qualify for evaluation via the public healthcare system at one of Sweden’s oncogenetic clinics in Lund, Gothenburg, Linköping, Stockholm, Uppsala, or Umeå. Research shows, however, that many carriers (i.e. those with pathogenic genetic variants) cannot be identified using today’s clinical criteria. Those who do meet the criteria may encounter long wait times or a series of hospital visits. GeneMate® is criteria-free, utilizes at-home sample collection, and has a turnaround time of 4-6 weeks. Genetic counseling is offered by phone. Quite simply, we meet you where you are.

2 NCCN, ASCO, ACMG and CDC

Looking for more on hereditary cancer?